Terms: = Lymphoma AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Clinical Outcome
26 results:
1. Early changes in soluble intracellular adhesion molecule-1 as prognostic biomarkers to immune checkpoint inhibitor.
Ji D; Jiang S; Zhang Q; Wang YK; Zhang J; Shen W; Li W; Liu R; Wang J; Mavis C; Gu JJ; Hu X
Clin Transl Sci; 2023 Aug; 16(8):1396-1407. PubMed ID: 37317057
[TBL] [Abstract] [Full Text] [Related]
2. clinical significance of plasma pd-l1
Xu P; Liu J; Chen H; Shang L; Wang F; Zhu Y; Guo Y; Li F; Yan F; Xie X; Li L; Gu W; Lin Y
Ann Hematol; 2023 Sep; 102(9):2435-2444. PubMed ID: 37162517
[TBL] [Abstract] [Full Text] [Related]
3. Coexpression of pd-l1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal lymphoma.
Saber MM
J Immunol Res; 2023; 2023():4556586. PubMed ID: 36726488
[TBL] [Abstract] [Full Text] [Related]
4. Molecular profiling of EBV associated diffuse large B-cell lymphoma.
Frontzek F; Staiger AM; Wullenkord R; Grau M; Zapukhlyak M; Kurz KS; Horn H; Erdmann T; Fend F; Richter J; Klapper W; Lenz P; Hailfinger S; Tasidou A; Trautmann M; Hartmann W; Rosenwald A; Quintanilla-Martinez L; Ott G; Anagnostopoulos I; Lenz G
Leukemia; 2023 Mar; 37(3):670-679. PubMed ID: 36604606
[TBL] [Abstract] [Full Text] [Related]
5.
Qiu L; Tang G; Li S; Vega F; Lin P; Wang SA; Wang W; Iyer SP; Malpica L; Miranda RN; Konoplev S; Tang Z; Fang H; Medeiros LJ; Xu J
Haematologica; 2023 Jun; 108(6):1604-1615. PubMed ID: 36453104
[TBL] [Abstract] [Full Text] [Related]
6. [Expression of pd-l1 and PD-1 in Pathological Tissue of Patients Newly Diagnosed with Diffuse Large B-Cell lymphoma].
Bao F; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):778-783. PubMed ID: 35680805
[TBL] [Abstract] [Full Text] [Related]
7. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
Tanaka N; Mori S; Kiyotani K; Ota Y; Gotoh O; Kusumoto S; Nakano N; Suehiro Y; Ito A; Choi I; Ohtsuka E; Hidaka M; Nosaka K; Yoshimitsu M; Imaizumi Y; Iida S; Utsunomiya A; Noda T; Nishikawa H; Ueda R; Ishida T
Haematologica; 2022 Oct; 107(10):2418-2431. PubMed ID: 35417939
[TBL] [Abstract] [Full Text] [Related]
8. Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome.
Di Raimondo C; Rubio-Gonzalez B; Palmer J; Weisenburger DD; Zain J; Wu X; Han Z; Rosen ST; Song JY; Querfeld C
Br J Dermatol; 2022 Aug; 187(2):234-243. PubMed ID: 35194801
[TBL] [Abstract] [Full Text] [Related]
9. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.
You H; Xu-Monette ZY; Wei L; Nunns H; Nagy ML; Bhagat G; Fang X; Zhu F; Visco C; Tzankov A; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Van Krieken JH; Piris MA; Winter JN; Li Y; Au Q; Xu B; Albitar M; Young KH
Oncoimmunology; 2021; 10(1):1928365. PubMed ID: 34350060
[TBL] [Abstract] [Full Text] [Related]
10. DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.
Xue X; Huang W; Qiu T; Guo L; Ying J; Lv N
BMC Cancer; 2020 Aug; 20(1):816. PubMed ID: 32854650
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.
Zhou H; Xu-Monette ZY; Xiao L; Strati P; Hagemeister FB; He Y; Chen H; Li Y; Manyam GC; Li Y; Montes-Moreno S; Piris MA; Young KH
Blood Cancer J; 2020 May; 10(5):49. PubMed ID: 32366834
[TBL] [Abstract] [Full Text] [Related]
12. Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence.
Huemer F; Leisch M; Geisberger R; Melchardt T; Rinnerthaler G; Zaborsky N; Greil R
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325898
[TBL] [Abstract] [Full Text] [Related]
13. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in lymphoma.
Mondello P; Tadros S; Teater M; Fontan L; Chang AY; Jain N; Yang H; Singh S; Ying HY; Chu CS; Ma MCJ; Toska E; Alig S; Durant M; de Stanchina E; Ghosh S; Mottok A; Nastoupil L; Neelapu SS; Weigert O; Inghirami G; Baselga J; Younes A; Yee C; Dogan A; Scheinberg DA; Roeder RG; Melnick AM; Green MR
Cancer Discov; 2020 Mar; 10(3):440-459. PubMed ID: 31915197
[No Abstract] [Full Text] [Related]
14. Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation.
Ortega Sanchez G; Stenner F; Dirnhofer S; Passweg J; Gerull S; Halter JP; Zippelius A; Läubli H
Swiss Med Wkly; 2019 Nov; 149():w20150. PubMed ID: 31707719
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx.
Chen PH; Yang Y; O'Malley DP; Xu ML
Ann Diagn Pathol; 2019 Aug; 41():129-135. PubMed ID: 31247533
[TBL] [Abstract] [Full Text] [Related]
16. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/pd-l1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract] [Full Text] [Related]
17. pd-l1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
[TBL] [Abstract] [Full Text] [Related]
18. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.
Mastaglio S; Wong E; Perera T; Ripley J; Blombery P; Smyth MJ; Koldej R; Ritchie D
Blood Adv; 2018 Feb; 2(4):335-346. PubMed ID: 29449224
[TBL] [Abstract] [Full Text] [Related]
19. NK/T Cell lymphoma: Updates in Therapy.
Suzuki R
Curr Hematol Malig Rep; 2018 Feb; 13(1):7-12. PubMed ID: 29368155
[TBL] [Abstract] [Full Text] [Related]
20. Novel Insights into Membrane Targeting of B Cell lymphoma.
de Winde CM; Elfrink S; van Spriel AB
Trends Cancer; 2017 Jun; 3(6):442-453. PubMed ID: 28718418
[TBL] [Abstract] [Full Text] [Related]
[Next]
